 This is a non-inferior study. The planned sample size was 358 patients, allowing for a 10 dropout rate and assuming the median progression free survival was 5.5 months in the experimental group and 4 months in the control group with a hazard ratio of 0.727, α0.05, β0.2. The planned enrolled time was 36 months and 12 months of follow up. The ratio between control and experimental group is 1:1. 